European Union - English - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, hepatic - various alimentary tract and metabolism products - treatment of acute hepatic porphyria (ahp) in adults and adolescents aged 12 years and older.

European Union - English - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - other alimentary tract and metabolism products, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

European Union - English - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - other nervous system drugs - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

European Union - English - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amyloidosis, familial - other nervous system drugs - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Canada - English - Health Canada

alnylam netherlands b.v. - patisiran (patisiran sodium) - solution - 2mg - patisiran (patisiran sodium) 2mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

alnylam netherlands b.v. - givosiran (givosiran sodium) - solution - 189mg - givosiran (givosiran sodium) 189mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

alnylam netherlands b.v. - lumasiran (lumasiran sodium) - solution - 94.5mg - lumasiran (lumasiran sodium) 94.5mg

Canada - English - Health Canada

alnylam netherlands b.v. - vutrisiran (vutrisiran sodium) - solution - 25mg - vutrisiran (vutrisiran sodium) 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alnylam australia pty ltd - patisiran, quantity: 10 mg - injection, concentrated - excipient ingredients: peg2000-c-dmg; sodium chloride; dlin-mc3-dma; water for injections; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; cholesterol; distearoylphosphatidylcholine - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

taiba al khaleej store netherlands - 1 glass vial(0.5ml) - injection - 94.5mg/0.5ml - urinary system-n/a